Core Insights - A recent multi-center study published in the American Journal of Hematology indicates that some patients with idiopathic multicentric Castleman disease (iMCD-TAFRO) may not require long-term maintenance therapy after achieving remission [1] Group 1: Study Findings - The study involved 27 patients with iMCD-TAFRO who maintained stable conditions after stopping treatment, with a median follow-up of 31 months [1] - Out of these, 23 patients continued to show stable conditions, and 20 patients achieved complete remission [1] - The study predicts that the proportion of patients maintaining stable conditions after stopping treatment is 96.3% at 6 months, 85.2% at 1 year, and 85.2% at 3 years [1] Group 2: Clinical Implications - The findings suggest that for some iMCD-TAFRO patients who achieve biochemical complete remission, attempting to stop treatment could be a viable clinical option [1]
我国研究显示这类严重罕见病或无需终身治疗
Xin Lang Cai Jing·2026-02-21 08:58